B7-H3
B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved.
Overview
B7-H3 (CD276) is an immune checkpoint-like molecule broadly overexpressed in solid tumours with limited normal expression; its function is debated, inhibiting T-cell activation and promoting tumour cell migration. Expression is more homogeneous than many ADC targets, found in 60-70% of small-cell lung cancer and 80-90% of castration-resistant prostate cancer by IHC, as well as head and neck and paediatric solid tumours. Ifinatamab deruxtecan (I-DXd) has shown high response rates in small-cell lung cancer and is in phase 3. B7-H3 is also pursued with radioligands and CAR-T. Whether its immune-dampening role means antibodies against it add an immunological benefit beyond payload delivery is unresolved. The simple version is a widely present tumour surface protein now used mainly as an address for ADCs.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved.
- 1 · What it is
B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved.
- 2 · What goes wrong in cancer
Function debated: inhibits T-cell activation, promotes tumour cell migration. Expression is more homogeneous than many ADC targets.
- 3 · How drugs use it
No product in this corpus aims at B7-H3 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Catalysts
Catalyst calendar- 2027expectedIDeate-Lung02: ifinatamab deruxtecan versus chemotherapy, relapsed small-cell lung cancer
Pivotal phase 3 for the B7-H3 ADC from the Merck and Daiichi Sankyo collaboration. Timing is a registry-based estimate. Source
External identifiers
Biology
Function debated: inhibits T-cell activation, promotes tumour cell migration. Expression is more homogeneous than many ADC targets.
- Small-cell lung cancer
- Prostate
- Head and neck
- Paediatric solid tumours
How often this target appears
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 80-90% | IHC, any expression | Castration-resistant disease | Wikipedia |
| Small-cell lung cancer | 60-70% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"B7-H3" OR ABSTRACT:"B7-H3" OR TITLE:"CD276" OR ABSTRACT:"CD276") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about B7-H3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNectin-4
Shares Aktis Oncology and the tag adc-target.
- TargetCEACAM5
Shares Lineage plasticity & neuroendocrine transformation and the tag adc-target.
- TargetHER2
Shares Alpha radioligands after ADC failure, Osteosarcoma and the tag adc-target.
- TargetTROP2
Shares Alpha radioligands after ADC failure and the tag adc-target.
- TargetDLL3
Shares Lineage plasticity & neuroendocrine transformation, Small-cell lung cancer, Prostate cancer.
- PathwayProstate cancer (KEGG map)
Shares Lineage plasticity & neuroendocrine transformation, Prostate cancer.
- CompanyBristol Myers Squibb
- InstitutionUppsala University Hospital / Uppsala University
Shares Glioma & glioblastoma, Prostate cancer.